Company: INDP
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001493152-25-010137
Chunk: 2

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 2
---
 of up to 10,000,000 shares of our common stock, par value $0.01 per share.

This Post-Effective Amendment No. 1 is being filed by the Registrant to update and supplement information contained in the Registration Statement, and also to include updated financial information.

No additional securities are being registered under this Post-Effective Amendment No. 1. This Post-Effective Amendment No. 1 concerns only the sale of shares of our common stock by the selling stockholder from time to time.

All filing fees payable in connection with the registration of these securities were previously paid in connection with the initial filing of the Registration Statement.

The information in this preliminary prospectus is not complete and may be changed. The selling stockholder may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state or jurisdiction where the offer or sale is not permitted.

<div align='center'>SUBJECT TO COMPLETION, DATED MARCH 13, 2025</div>

PROSPECTUS

<div align='center'>Indaptus Therapeutics, Inc.

10,000,000 Shares of Common Stock</div>

This prospectus relates to the offer and sale of up to 10,000,000 shares of our common stock, par value $0.01 per share, by YA II PN, LTD., or YA or the selling stockholder, a Cayman Islands exempt limited partnership.

The shares of common stock being offered by the selling stockholder are to be issued pursuant to the Standby Equity Purchase Agreement dated February 12, 2025 that we entered into with YA, or the Purchase Agreement. We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of our shares by the selling stockholder. However, we may receive up to $20.0 million in aggregate gross proceeds from sales of our shares to YA that we may make under the Purchase Agreement, from time to time during the 36 months following the execution of the Purchase Agreement, or the Advance Shares. Pursuant to the Purchase Agreement, we issued 305,960 shares of common stock to YA as consideration for its irrevocable commitment to purchase our shares of common stock under the Purchase Agreement, or the Commitment Shares. The additional 9,694,040 shares of common stock representing Advance Shares, that may be offered